What is Cognoptix?
Cognoptix is a pioneering biotechnology firm dedicated to the early detection and diagnosis of Alzheimer's Disease through its innovative Sapphire II system. By utilizing a non-invasive beta amyloid eye scanning test, the company provides a scalable, cost-effective diagnostic solution that can be seamlessly integrated into standard clinical workflows. Founded by Dr. Lee Goldstein and Dr. Leo Chylack, the organization bridges the gap between advanced optical science and neurology, aiming to empower physicians with actionable data for early patient intervention. The company's market position is defined by its focus on high-precision diagnostics, positioning it as a critical player in the broader neuro-health ecosystem.
How much funding has Cognoptix raised?
Cognoptix has raised a total of $42.1M across 6 funding rounds:
Series A
$1M
Series B
$18.5M
Series C
$4.6M
Debt
$390K
Series D
$15M
Other Financing Round
$2.6M
Series A (2007): $1M, investors not publicly disclosed
Series B (2008): $18.5M led by Inventages
Series C (2011): $4.6M, investors not publicly disclosed
Debt (2014): $390K featuring Inventages
Series D (2014): $15M backed by Inventages, Alopexx, and Launchpad Venture Group LLC
Other Financing Round (2020): $2.6M with participation from Harvard Business School Alumni Angels of Greater New York, New York Angels Inc, and Launchpad Venture Group LLC
Key Investors in Cognoptix
Inventages
Inventages is a premier life-sciences and wellness-focused venture capital firm that provides strategic guidance and financial support to companies at the intersection of nutrition and medicine.
Launchpad Venture Group LLC
Launchpad Venture Group is a prominent network of angel investors providing both financial and human capital to science-driven startups, with a strong emphasis on mentorship and long-term growth.
Alopexx
Alopexx is a clinical-stage biotechnology company specializing in the development of novel immune-mediated therapeutics for the prevention and treatment of complex microbial infections.
What's next for Cognoptix?
With the recent infusion of capital, Cognoptix is poised to deepen its strategic alliances with pharmaceutical partners and academic institutions. The focus remains on transitioning the Sapphire II platform from clinical validation to widespread commercial adoption. As the company scales, it will likely prioritize regulatory milestones and the expansion of its diagnostic footprint, ensuring that its technology becomes a standard tool in the early management of cognitive health. The firm's ability to maintain its momentum will be contingent upon its success in navigating complex clinical trials and securing long-term partnerships that facilitate market penetration.
See full Cognoptix company page
